Savolitinib. Hepatocyte growth factor receptor (HGFR, MET, c-Met) inhibitor, Cancer therapy
Mesenchymal-epithelial transition factor (c-Met), a tyrosine kinase, is a proto-oncogene encoding the high-affinity receptor for hepatocyte growth factor (HGF). Under pathological conditions c-Met activation may confer proliferative, survival and invasive/metastatic abilities to cancer cells. Indeed, c-Met is overexpressed in a wide array of carcinomas including lung, breast, ovary, kidney, colon, thyroid, liver and gastric carcinomas. Savolitinib (AZD-6094) is a potent and selective small-molecule c-Met kinase inhibitor with IC50 values in the low nanomolar range in enzyme assays which has been found to inhibit c-Met autophosphorylation and HGF-induced proliferation in human lung cancer cell lines. In a phase II clinical study in MET-driven papillary renal cell carcinoma (PRCC), patients receiving orally administered savolitinib displayed a partial response rate of 18% and a progression-free survival of 6.2 months in comparison with 1.4 months in MET-independent patients. Currently, a phase III clinical trial (SAVOIR) is ongoing to study the efficacy of savolitinib in comparison with sunitinib in patients with MET-driven PRCC..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:043 |
|---|---|
| Enthalten in: |
Drugs of the future - 043(2018), 1, Seite 0005 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gras,US!aJ. [VerfasserIn] |
|---|
| BKL: |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
OLC2000499880 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2000499880 | ||
| 003 | DE-627 | ||
| 005 | 20230516073303.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180809s2018 xx |||||o 00| ||eng c | ||
| 028 | 5 | 2 | |a fidpha__2018-08-09.pp |
| 035 | |a (DE-627)OLC2000499880 | ||
| 035 | |a (DE-599)GBVOLC2000499880 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |
| 084 | |a PHARM |2 fid | ||
| 084 | |a 44.40 |2 bkl | ||
| 100 | 1 | |a Gras,US!aJ. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Savolitinib. Hepatocyte growth factor receptor (HGFR, MET, c-Met) inhibitor, Cancer therapy |
| 264 | 1 | |c 2018 | |
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Mesenchymal-epithelial transition factor (c-Met), a tyrosine kinase, is a proto-oncogene encoding the high-affinity receptor for hepatocyte growth factor (HGF). Under pathological conditions c-Met activation may confer proliferative, survival and invasive/metastatic abilities to cancer cells. Indeed, c-Met is overexpressed in a wide array of carcinomas including lung, breast, ovary, kidney, colon, thyroid, liver and gastric carcinomas. Savolitinib (AZD-6094) is a potent and selective small-molecule c-Met kinase inhibitor with IC50 values in the low nanomolar range in enzyme assays which has been found to inhibit c-Met autophosphorylation and HGF-induced proliferation in human lung cancer cell lines. In a phase II clinical study in MET-driven papillary renal cell carcinoma (PRCC), patients receiving orally administered savolitinib displayed a partial response rate of 18% and a progression-free survival of 6.2 months in comparison with 1.4 months in MET-independent patients. Currently, a phase III clinical trial (SAVOIR) is ongoing to study the efficacy of savolitinib in comparison with sunitinib in patients with MET-driven PRCC. | ||
| 773 | 0 | 8 | |i Enthalten in |t Drugs of the future |d Barcelona : Prous Science - Thomson Reuters, 1976 |g 043(2018), 1, Seite 0005 |w (DE-627)13048489X |w (DE-600)752959-4 |w (DE-576)016071395 |x 0377-8282 |7 nnns |
| 773 | 1 | 8 | |g volume:043 |g year:2018 |g number:1 |g pages:0005 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_4125 | ||
| 936 | b | k | |a 44.40 |q AVZ |
| 951 | |a AR | ||
| 952 | |d 043 |j 2018 |e 1 |h 0005 | ||